SEHK:6855Biotechs
Assessing Ascentage Pharma (SEHK:6855) Valuation Following Major Data Publication on Olverembatinib in Rare GIST Subtype
Ascentage Pharma Group International (SEHK:6855) garnered investor interest after publishing new data from a Phase Ib study for its drug olverembatinib in patients with SDH-deficient gastrointestinal stromal tumors.
See our latest analysis for Ascentage Pharma Group International.
Following the announcement of encouraging new results for olverembatinib, Ascentage Pharma Group International has continued to capture investor attention, even as its share price has pulled back 6.4% over the past...